MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1
Open accessThe DOI matches its Crossref record.
Abstract
MicroRNAs (miRNAs) are emerging as important modulators in cellular pathways and they appear to play a key role in tumorigenesis. MiR-145 is downregulated in several human malignancies, including lung cancer, but the responsible molecular mechanisms remain unclear. We previously reported that restoration of hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation. This study showed that hsa-miR-145 targets EGFR and nucleoside diphosphate linked moiety X-type motif 1 (NUDT1 or MTH1) in lung adenocarinoma cells. The mRNA expressions of EGFR and NUDT1 were significantly downregulated after miR-145 transfection in human lung adenocarcinoma cells. Our results demonstrated miR-145 in the negative regulation of EGFR and NUDT1 expressions at both mRNA and protein levels. Further analysis showed that miR-145 has the ability to inhibit cell proliferation on transfected lung adenocarcinoma cells over three time points (24, 48 and 72 hours). Upregulation of miR-145 appeared to be an important gene regulation mechanism for the proliferation of lung adenocarcinoma cells and it correlated strongly with the downregulation of EGFR and NUDT1. Interestingly, our study revealed that the altered proliferation in lung cancer cells is not accompanied by changes in apoptosis. Our findings provided new insight into the complex regulating pathway comprising of miR-145, EGFR, NUDT1 and other unknown factors which function in cell proliferation but not in apoptosis. Understanding miR-145's targets and its regulating pathways may lead to new therapeutic strategies for lung adenocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Alexander, M. R., & Owens, G. K. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142315 · Cited by 773
MicroRNAs and complex diseases: from experimental results to computational models
Chen, X., Xie, D., Zhao, Q., & You, Z.-H. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbx130 · Cited by 638
MicroRNAs in Common Human Diseases
Li, Y., & Kowdley, K. V. (2012) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2012.07.005 · Cited by 360
MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis
Xu, Q., Liu, L.-Z., Qian, X., Chen, Q., Jiang, Y., Li, D., Lai, L., & Jiang, B.-H. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr730 · Cited by 284
lincRNA-RoR and miR-145 Regulate Invasion in Triple-Negative Breast Cancer via Targeting ARF6
Eades, G., Wolfson, B., Zhang, Y., Li, Q., Yao, Y., & Zhou, Q. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0251 · Cited by 271
Abdollahzadeh, R., Daraei, A., Mansoori, Y., Sepahvand, M., Amoli, M. M., & Tavakkoly‐Bazzaz, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27941 · Cited by 261
MicroRNAs as therapeutic targets and their potential applications in cancer therapy
Cho, W. C. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.696102 · Cited by 70
Self-citationThe emerging functions of the p53-miRNA network in stem cell biology
Lin, C.-P., Choi, Y. J., Hicks, G. G., & He, L. (2012) · Cell Cycle · doi:10.4161/cc.20207 · Cited by 38
Cao, H., Jia, C., Li, Z., Yang, H., Fang, R., Zhang, Y., & Cui, Y. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02587-w · Cited by 12
Metadata
- Authors
- Cho, W. C., Chow, A. S., & Au, J. S.
- Venue
- RNA Biology
- Publisher
- Informa UK Limited
- Published
- 2011-01
- Volume
- 8
- Issue
- 1
- Pages
- 125-131
- ISSN
- 1547-6286 (ISSN-L)
- 1555-8584
- OpenAlex
- W2091166689
- Cited by
- 220
- References
- 0
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.